National Hospital of Sri Lanka’s Rs12bn, 16-storey heart centre tests UAE cardiac referrals

National Hospital of Sri Lanka plans a Rs. 12 billion, 16-storey heart centre for 2026, giving UAE cardiac operators a 2029 marker for South Asia referral risk.

For UAE hospital CEOs, CFOs and COOs, the issue is practical: a stronger public cardiac hub in Colombo could retain patients who now travel for capacity, waiting-time and payer reasons.

What Sri Lanka approved

Sri Lankan Health Minister Nalinda Jayatissa said construction at the National Hospital of Sri Lanka is scheduled to begin in 2026 and finish within 3 years, according to Newswire. The announcement came on 15 June 2026, during the assumption of duties by Specialist Dr. M.K. Sampath Indika Kumara as Deputy Director General of the National Hospital.

"The National Hospital of Sri Lanka should become the foremost hospital in Asia."
Nalinda Jayatissa, Minister of Health, Sri Lanka

Jayatissa also said discussions had been held on a stroke unit within the same hospital premises, according to Newswire. Cardiac and stroke services share expensive capacity, including cath labs, intensive care beds, imaging, emergency transfer protocols and consultant rotas, so the 16-storey project points to a broader tertiary-care push in Colombo.

What UAE operators should track

The commercial question for UAE providers is whether the Colombo project keeps more Sri Lankan, Maldivian and South Asian cardiac patients closer to home. International patient teams in Dubai, Abu Dhabi and the Northern Emirates should treat 2026-2029 as the planning window for elective valve, bypass, electrophysiology and structural-heart programmes.

• CEOs can track whether Sri Lanka uses the centre to market public-sector tertiary care across South Asia.
• CFOs can test international cardiac revenue exposure if 5-10% of Sri Lankan self-pay cases remain in Colombo.
• COOs can review transfer agreements, interpreter coverage and fast-track cardiac pathways before 2029.
• CMOs can compare UAE cardiac package pricing with Colombo alternatives during 2027 contracting cycles.

The demand case is clear. A UNDP UAE NCD investment case said cardiovascular disease accounted for 34% of all deaths in the UAE, while World Health Organization data put cardiovascular disease at an estimated 17.9 million deaths globally each year. Zavis analysis is that regional cardiac hubs can coexist, but speed, outcomes reporting and payer access will decide which centres win mobile patients.

Regulatory and procurement markers

Any UAE operator adding cardiac capacity still works under local regulators. In Dubai, the Dubai Health Authority (DHA) licenses health facilities and professionals; DHA said it issued licences to more than 150 healthcare facilities and 800 healthcare professionals in the first quarter of 2024. In Abu Dhabi and Al Ain, the Department of Health - Abu Dhabi (DOH) sets facility, professional and insurance requirements. In the Northern Emirates, the Ministry of Health and Prevention (MOHAP) remains the federal regulator.

For CIOs and medical directors, the response is clinical governance as much as sales. International cardiac patients need pre-arrival diagnostics, image transfer, consent in the right language, post-discharge monitoring and complication pathways. If those processes are fragmented, a lower-cost public cardiac centre with a 3-year opening horizon can take share without matching UAE hotel-grade service.

The next marker is procurement. If Sri Lanka tenders cath labs, cardiac ICU equipment, imaging systems and operating-theatre packages in 2026 or 2027, UAE suppliers and hospital groups will get a clearer read on the centre's service mix. Until then, the number to remember is 2029, when UAE cardiac programmes may face a stronger Colombo competitor for South Asia referrals.